A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
Primary Objective: To evaluate the safety, tolerability, and dose-limiting toxicity of anti-CD70 chimeric antigen receptor allogeneic T-cell injection (CHT101) in the treatment of CD70-positive relapsed/refractory T-cell and B-cell hematological malignancies. Secondary Objectives: To characterize the PK profiles of CHT101; to evaluate the clinical efficacy of CHT101 for CD70-positive relapsed/refractory T-cell and B-cell hematological malignancies. Indication: CD70-positive relapsed/refractory T-cell and B-cell hematological malignancies
Epistemonikos ID: 342ed88f40dd3445fb1b04e7fe29bdd7e2b2b2b6
First added on: Sep 10, 2026